Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$330.3M
83M shares
52-week range
$0.90 – $5.81
64% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.89%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $589.0K | $39.9M | $19.0M | $11.0M | $14.2M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $589.0K | $39.9M | $19.0M | $11.0M | $14.2M |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $2.4M | $6.6M | $15.2M | $14.4M | $17.7M | $26.9M | $30.8M |
| Operating income | −$4.2M | −$20.0M | −$22.7M | $18.2M | −$10.6M | −$62.1M | −$38.6M |
| EBITDA | −$4.8M | −$17.8M | −$56.7M | $18.2M | −$10.0M | −$57.5M | −$48.1M |
| Net income | −$6.2M | −$24.6M | −$56.7M | $17.9M | −$10.0M | −$57.5M | −$49.6M |
| Net margin | — | — | -9625.3% | 44.9% | -52.4% | -523.4% | -349.3% |
| EPS (diluted) | -0.87 | -5.28 | -3.82 | 0.87 | -0.46 | -2.15 | -0.80 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $16M | $-1.13 | $-1.37–$-0.21 | 12 |
| 2027 | $15M | $-0.76 | $-1.13–$-0.42 | 10 |
| 2028 | $47M | $-0.35 | $-0.55–$-0.12 | 10 |
| 2029 | $150M | $0.00 | $0.00–$0.00 | 4 |
Forward consensus · source: Financial Modeling Prep
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
www.opusgtx.comNo one on the platform currently holds IRD.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 73,209 | $333.1K |
No one on the platform has traded IRD yet.
| $80M |
| — |
| HURATuHURA Biosciences, Inc. | $2.29 | +6.02% | $146M | — |
| INOInovio Pharmaceuticals, Inc. | $1.12 | +1.82% | $60M | — |
Source: Financial Modeling Prep · peers by sector/industry
$IRD WE only need some Volume then we will move north
View on StockTwits ↗Effective 6/29 ~$12.2T in assets now tracking these names: $ZN — AI at the intersection of insurance & mobility. Joins Russell 2000 + 3000 after strong traction in underwriting & fleet safety $ZENA — Tech play added to the Russell 3000, opening the door to massive institutional index exposure $IRD — Gene therapy for inherited retinal diseases. Added to Russell 2000, 3000 & Microcap — big liquidity unlock for a small biotech $ALOY — Specialty alloys producer entering the Russell 3000 as an institutional visibility catalyst
View on StockTwits ↗The annual Russell Index reconstitution takes effect on June 29, driving passive flows across roughly $12.2T in tracking assets. Key component additions to monitor for volume changes include: $ZN joining the Russell 2000 and 3000; $ZENA added to the Russell 3000; $IRD added to the Russell 2000, 3000, and Microcap; $ALOY entering the Russell 3000; and $FJET joining the Russell 3000 within 7 months of its listing. Institutional inflows and volume shifts on these small caps will be a primary focus.
View on StockTwits ↗$IRD gained Russell index inclusion, joining the Russell 3000, 2000 and Microcap indexes effective June 29, 2026.
View on StockTwits ↗$LASE $IRD $GRI If you lost money because of this pumper you can get a lawyer
View on StockTwits ↗$IRD lets do the 4.64$ JUMP to Switch Info bullish Chart area
View on StockTwits ↗$IRD a Close above 4.64 and the charf is bullish again
View on StockTwits ↗$IRD Let’s GO to $11++!! 💹💵 $SNBR Don’t Sleep on it!!🏝️ 😂 🛏️ $RYCEY Too Easy @ .87 avg! 🏎️ 🛫 $HOOD Moving!!! 🤩 🏝️
View on StockTwits ↗$IRD News https://ir.opusgtx.com/press-releases/detail/535/opus-genetics-highlights-five-gene-therapy-programs-targeting-significant-unmet-need-in-patients-with-inherited-retinal-diseases
View on StockTwits ↗$IRD conducted a virtual R&D Science Forum corporate presentation on June 16.
View on StockTwits ↗$IRD dilution like clockwork https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0001140361-26-024283/ny20075388x1_s3.htm
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.